These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24533458)

  • 1. Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis.
    Gupta A; Pant G; Mitra K; Madan J; Chourasia MK; Misra A
    Mol Pharm; 2014 Apr; 11(4):1201-7. PubMed ID: 24533458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy.
    Gupta A; Sharma D; Meena J; Pandya S; Sachan M; Kumar S; Singh K; Mitra K; Sharma S; Panda AK; Gupta P; Gupta UD; Misra A
    Pharm Res; 2016 Aug; 33(8):1899-912. PubMed ID: 27095353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalable microparticles containing nitric oxide donors: saying NO to intracellular Mycobacterium tuberculosis.
    Verma RK; Singh AK; Mohan M; Agrawal AK; Verma PR; Gupta A; Misra A
    Mol Pharm; 2012 Nov; 9(11):3183-9. PubMed ID: 22978290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Mycobacterium tuberculosis-Infected Macrophages with Poly(Lactic-Co-Glycolic Acid) Microparticles Drives NFκB and Autophagy Dependent Bacillary Killing.
    Lawlor C; O'Connor G; O'Leary S; Gallagher PJ; Cryan SA; Keane J; O'Sullivan MP
    PLoS One; 2016; 11(2):e0149167. PubMed ID: 26894562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable microparticles containing large payload of anti-tuberculosis drugs.
    Muttil P; Kaur J; Kumar K; Yadav AB; Sharma R; Misra A
    Eur J Pharm Sci; 2007 Oct; 32(2):140-50. PubMed ID: 17681458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
    Verma RK; Agrawal AK; Singh AK; Mohan M; Gupta A; Gupta P; Gupta UD; Misra A
    Tuberculosis (Edinb); 2013 Jul; 93(4):412-7. PubMed ID: 23562366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
    Ohashi K; Kabasawa T; Ozeki T; Okada H
    J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages.
    Hirota K; Hasegawa T; Hinata H; Ito F; Inagawa H; Kochi C; Soma G; Makino K; Terada H
    J Control Release; 2007 May; 119(1):69-76. PubMed ID: 17335927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.
    Sharma R; Muttil P; Yadav AB; Rath SK; Bajpai VK; Mani U; Misra A
    J Antimicrob Chemother; 2007 Mar; 59(3):499-506. PubMed ID: 17242031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
    Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
    Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.
    Sharma R; Saxena D; Dwivedi AK; Misra A
    Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting.
    Nasr M; Awad GA; Mansour S; Taha I; Al Shamy A; Mortada ND
    Eur J Pharm Biopharm; 2011 Nov; 79(3):601-11. PubMed ID: 21827854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis.
    Gupta A; Meena J; Sharma D; Gupta P; Gupta UD; Kumar S; Sharma S; Panda AK; Misra A
    Mol Pharm; 2016 Sep; 13(9):3247-55. PubMed ID: 27463245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages.
    Lawlor C; O'Sullivan MP; Sivadas N; O'Leary S; Gallagher PJ; Keane J; Cryan SA
    Mol Pharm; 2011 Aug; 8(4):1100-12. PubMed ID: 21591762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of highly porous large PLGA microparticles for pulmonary drug delivery.
    Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y
    Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Mol Pharm; 2016 Mar; 13(3):979-89. PubMed ID: 26808409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
    Devrim B; Bozkır A; Canefe K
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.
    O'Connor G; Krishnan N; Fagan-Murphy A; Cassidy J; O'Leary S; Robertson BD; Keane J; O'Sullivan MP; Cryan SA
    Eur J Pharm Biopharm; 2019 Jan; 134():153-165. PubMed ID: 30385419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis.
    Hirota K; Hasegawa T; Nakajima T; Inagawa H; Kohchi C; Soma G; Makino K; Terada H
    J Control Release; 2010 Mar; 142(3):339-46. PubMed ID: 19951729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
    Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
    J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.